Abstract：Objective To investigate the relative factors of bone metastasis in breast cancer. Methods The clinical data of 291 breast cancer patients from July 2013 to June 2017 were analyzed retrospectively. The single factor analysis was applied to the collected clinical factors, and then the meaningful items were analyzed by Logistic regression. Results Bone metastasis was found in 53 of 291 patients (18. 2%), 3 of them lack Ⅰ~Ⅳ stage, N stage, 2 cases lack T stage, 3 negative, lymph node metastasis, not included in the table analysis. The results showed that clinical stage, T stage, N stage, size of primary tumor and lymph node metastasis might be correlated with bone metastasis of breast cancer (P<0.05). Five variables with statistical difference were analyzed by Logistic regression analysis. The results showed that clinical stage was a risk factor for bone metastasis of breast cancer (P<0.05). Bone metastasis occurred within 5 years after diagnosis. Axial bone was the most common metastatic site, but bone metastasis of limbs was not uncommon.Conclusion Clinical staging is an independent risk factor for bone metastasis in breast cancer. The metastatic site of breast cancer is mainly axial bone, but metastasis to extremities is not uncommon.
张森, 陈强, 刘玲. 291例乳腺癌患者核素骨显像资料回顾性分析[J]. 医学临床研究, 2019, 36(2): 300-302.
ZHANG Sen, Chen Qiang, Liu Ling. Retrospective analysis on 291 cases of Radionuclide Bone Imaging in Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2019, 36(2): 300-302.
[1] Engel J, Eckel R, Aydemir ,et al. Determinants and prognoses of locoregional and distant progression in breast cancer[J].Int J Radiat Oncol Biology Phys,2003, 55(5): 1186-1195. [2] Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis[J].Clin Orthop Relat Res,1995, 312: 34. [3] Daisuke U, Shinya S, Masanori I, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT[J].Radiology,2006, 238(1): 264-271. [4] 侯先存, 周青, 李智勇, 等. 18F-FDG hPET/CT与99Tcm-MDP骨显像探测乳腺癌骨转移的对比研究[J].中国临床医学影像杂志,2010, 21(3): 197-200. [5] Rordorf T. Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup[J].Breast,2014, 23(5): 511-525. [6] 江泽飞, 陈佳艺, 牛晓辉, 等. 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2014版)[J].中华医学杂志, 2015, 95(4): 241-247. [7] 侯少洋, 张月梅, 王建军. 120例乳腺癌骨转移核素显像特点分析[J].中国肿瘤临床与康复, 2004, 11(4): 320-321. [8] 石根明, 王跃珍. 乳腺癌骨转移的危险因素分析[J].浙江医学, 2005, 27(1): 19-22. [9] 熊玲静, 梁昌华, 李新辉, 等. 乳腺癌骨转移与其生物学标记因子的关系[J].中华核医学与分子影像杂志, 2003, 23(4): 208-210. [10] Colleoni M, O’Neill A, Goldhirsch A, et al. Identifying Breast Cancer Patients at High Risk for Bone Metastases[J].J Clin Oncol,2000, 18(23): 3925-3935. [11] 李凯, 于飞, 李午生, 等. 乳腺癌骨转移的危险因素分析[J].中国医学工程,2011,19(5):7-8. [12] Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer[J].Oncologist,2004, 9(6): 606-616. [13] Zhu L, Loo WT, Cheng CW, et al. Possible predictive markers related to micro-metastasis in breast cancer patients[J].Oncol Rep,2006, 15(5): 1217-1223. [14] 黄之杰.放射性核素骨显像对乳腺癌骨转移的临床应用价值[J].西南国防医药, 2011, 21(8): 847-848.
2019, Vol. 36 
